0001562180-24-005791.txt : 20240717
0001562180-24-005791.hdr.sgml : 20240717
20240717195652
ACCESSION NUMBER: 0001562180-24-005791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240715
FILED AS OF DATE: 20240717
DATE AS OF CHANGE: 20240717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quigley Jill M.
CENTRAL INDEX KEY: 0001799780
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39926
FILM NUMBER: 241123475
MAIL ADDRESS:
STREET 1: TWO COMMERCE SQUARE, 2001 MARKET STREET
STREET 2: 28TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Terns Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001831363
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 650-525-5535 EXT.101
MAIL ADDRESS:
STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-07-15
false
0001831363
Terns Pharmaceuticals, Inc.
TERN
0001799780
Quigley Jill M.
C/O TERNS PHARMACEUTICALS, INC.
1065 EAST HILLSDALE BLVD., SUITE 100
FOSTER CITY
CA
94404
true
false
false
false
true
Common Stock
2024-07-15
4
M
false
14365.00
1.82
A
44365.00
D
Common Stock
2024-07-15
4
S
false
14365.00
10.0007
D
30000.00
D
Common Stock
2024-07-16
4
M
false
400.00
1.82
A
30400.00
D
Common Stock
2024-07-16
4
S
false
400.00
10.00
D
30000.00
D
Stock Option (Right to Buy)
1.82
2024-07-15
4
M
false
14365.00
0.00
D
2023-06-12
2032-06-15
Common Stock
14365.00
17635.00
D
Stock Option (Right to Buy)
1.82
2024-07-16
4
M
false
400.00
0.00
D
2023-06-12
2032-06-15
Common Stock
400.00
17235.00
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
This sale price represents the weighted average sale price of the shares sold ranging from $10.00 to $10.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option vested in full immediately prior to the Annual Meeting following the date of grant.
/s/ Bryan Yoon as Attorney-in-Fact for Jill M. Quigley
2024-07-17